Memantine in Patients With Chronic Glaucoma

This study has been completed.
Information provided by:
Allergan Identifier:
First received: August 31, 2005
Last updated: November 3, 2010
Last verified: November 2010
Randomized double-masked clinical trial of memantine in patients with glaucoma

Condition Intervention Phase
Open-Angle Glaucoma
Drug: memantine
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Allergan:

Primary Outcome Measures:
  • Progression of glaucoma

Enrollment: 1119
Study Start Date: March 1999
Study Completion Date: August 2006
Primary Completion Date: January 2006 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Glaucoma damage on examination of visual field and optic disc
  • Good visual acuity (with glasses if needed)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information Identifier: NCT00141882     History of Changes
Other Study ID Numbers: 192944-004 
Study First Received: August 31, 2005
Last Updated: November 3, 2010
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Glaucoma, Open-Angle
Eye Diseases
Ocular Hypertension
Anti-Dyskinesia Agents
Antiparkinson Agents
Central Nervous System Agents
Dopamine Agents
Excitatory Amino Acid Agents
Excitatory Amino Acid Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on May 02, 2016